ANI Pharmaceuticals Inc (ANIP)

Total asset turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	614,376	555,456	538,953	517,460	486,816	449,394	401,386	358,694	316,385	283,082	251,322	226,092	216,136	212,459	213,377	213,222	208,475	199,189	197,547	203,434
Total assets	US$ in thousands	1,283,700	1,287,380	920,753	914,524	904,422	889,914	859,341	765,224	760,087	739,110	751,334	744,846	771,598	470,454	480,159	463,843	461,190	462,581	465,391	482,232
Total asset turnover		0.48	0.43	0.59	0.57	0.54	0.50	0.47	0.47	0.42	0.38	0.33	0.30	0.28	0.45	0.44	0.46	0.45	0.43	0.42	0.42

December 31, 2024 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $614,376K ÷ $1,283,700K
= 0.48

The total asset turnover of ANI Pharmaceuticals Inc has shown fluctuations over the period from March 31, 2020, to December 31, 2024. The ratio started at 0.42 in March 2020 and remained relatively stable around this level until March 2021. Subsequently, there was a noticeable increase in the ratio, reaching 0.57 by March 31, 2024, indicating that the company generated $0.57 in revenue for every dollar of assets during that period.

However, there was some variability in the total asset turnover ratio during the interim periods, with fluctuations between 0.28 and 0.59. Despite this variability, the general trend shows an overall improvement in asset utilization efficiency over the years, as the ratio increased from 0.42 in March 2020 to 0.48 in December 31, 2024.

This upward trend suggests that ANI Pharmaceuticals Inc has been more effective in generating sales from its assets over the period under review, reflecting improved operational efficiency and potentially better management of its asset base.